[1] Cucinotta D, Vanelli M.WHO declares COVID-19 a pandemic[J]. Acta Biomed, 2020, 91(1): 157-160.
[2] Li H, Zhou Y, Zhang M, et al.Updated approaches against SARS-CoV-2[J]. Antimicrob Agents Chemother, 2020, 64(6):e00483-20.
[3] Greenwood B.The contribution of vaccination to global health: Past, present and future[J]. Philos Trans R Soc Lond B Biol Sci, 2014, 369(1645): 20130433.
[4] Frederiksen LSF, Zhang Y, Foged C, et al.The long road toward COVID-19 herd immunity: Vaccine platform technologies and mass immunization strategies[J].Front Immunol, 2020, 11:111817.
[5] Khoury DS, Cromer D, Reynaldi A, et al.Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection[J]. Nat Med, 2021, 27(7): 1205-1211.
[6] Zimmermann P, Curtis N.Factors that influence the immune response to vaccination[J]. Clin Microbiol Rev, 2019, 32(2):e00084-18.
[7] Zhao P, Cao J, Zhao LJ, et al.Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine[J]. Virology, 2005, 331(1): 128-135.
[8] Sauré D, O'Ryan M, Torres JP, et al. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: A sentinel surveillance study[J]. Lancet Infect Dis, 2022,22(1):56-63.
[9] CKP Mok, Cohen CA, Cheng SMS, et al.Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong[J]. Respirology, 2022,27(4):301-310.
[10] Scheiermann C, Gibbs J, Ince L, et al.Clocking in to immunity[J]. Nat Rev Immunol, 2018, 18(7): 423-437.
[11] Zhang H, Liu Y, Liu D, et al.Time of day influences immune response to an inactivated vaccine against SARS-CoV-2[J]. Cell Res, 2021, 31(11): 1215-1217.
[12] Long JE, Drayson MT, Taylor AE, et al.Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial[J]. Vaccine, 2016, 34(24): 2679-2685.
[13] Xia S, Zhang Y, Wang Y, et al.Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial[J]. Lancet Infect Dis, 2021, 21(1): 39-51.
[14] Zhang Y, Zeng G, Pan H, et al.Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial[J]. Lancet Infect Dis, 2021, 21(2): 181-192.
[15] Mitsunaga T, Ohtaki Y, Seki Y, et al.The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: A prospective study in Japan[J]. Peer J, 2021, 9:e12316.
[16] Barros-Martins J, Hammerschmidt SI, Cossmann A, et al.Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination[J].Nat Med,2021,27(9):1525-1529.
[17] Schmidt T, Klemis V, Schub D, et al.Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination[J]. Nat Med, 2021, 27(9): 1530-1535.
[18] Liu X, Shaw RH, Stuart ASV, et al.Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial[J]. Lancet, 2021, 398(10303): 856-869.
[19] Moghnieh R, Mekdashi R, El-Hassan S, et al.Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon[J]. Vaccine, 2021, 39(46): 6713-6719.
[20] Keskin AU, Bolukcu S, Ciragil P, et al.SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen[J]. J Med Virol, 2022, 94(1): 39-41.
[21] Toback S, Galiza E, Cosgrove C, et al.Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: An exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial[J].Lancet Respir Med, 2022,10(2):167-179.
[22] Lazarus R, Baos S, Cappel-Porter H, et al.Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): A multicentre, randomised, controlled, phase 4 trial[J].Lancet, 2021, 398(10318):2277-2287.
[23] Bastola R, Noh G, Keum T, et al.Vaccine adjuvants: Smart components to boost the immune system[J]. Arch Pharm Res, 2017, 40(11): 1238-1248.
[24] Jeong SK, Heo YK, Jeong JH, et al.COVID-19 subunit vaccine with a combination of TLR1/2 and TLR3 agonists induces robust and protective immunity[J]. Vaccines (Basel), 2021, 9(9):957.
[25] Frenck RW Jr, Klein NP, Kitchin N, et al.Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents[J]. N Engl J Med, 2021,385(3): 239-250.
[26] Klein SL, Jedlicka A, Pekosz A.The Xs and Y of immune responses to viral vaccines[J]. Lancet Infect Dis, 2010, 10(5): 338-349.
[27] Butterworth M, McClellan B, Allansmith M. Influence of sex in immunoglobulin levels[J]. Nature, 1967, 214(5094): 1224-1225.
[28] Klein SL, Marriott I, Fish E-N.Sex-based differences in immune function and responses to vaccination[J]. Trans R Soc Trop Med Hyg, 2015, 109(1): 9-15.
[29] Kageyama T, Ikeda K, Tanaka S, et al.Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan[J]. Clin Microbiol Infect, 2021, 27(12):1861.
[30] Salvagno GL, Henry BM, di Piazza G, et al. Anti-SARS-CoV-2 receptor-binding domain total antibodies response in seropositive and seronegative healthcare workers undergoing COVID-19 mRNA BNT162b2 vaccination[J]. Diagnostics (Basel), 2021, 11(5):832.
[31] Eibl MM, Wolf HM.Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities[J].Immunotherapy,2015, 7(12):1273-1292.
[32] Furer V, Eviatar T, Zisman D, et al.Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study[J].Ann Rheum Dis,2021,80(10):1330-1338.
[33] Berbudi A, Rahmadika N, Tjahjadi AI, et al.Type 2 diabetes and its impact on the immune system[J].Curr Diabetes Rev,2020,16(5):442-449.
[34] Glaser R, Kiecolt-Glaser JK, Bonneau RH, et al.Stress-induced modulation of the immune response to recombinant hepatitis B vaccine[J]. Psychosom Med, 1992, 54(1): 22-29.
[35] Kiecolt-Glaser JK, Glaser R, Gravenstein S, et al.Chronic stress alters the immune response to influenza virus vaccine in older adults[J]. Proc Natl Acad Sci USA,1996,93(7):3043-3047.
[36] Gallagher S, Phillips AC, Drayson MT, et al.Caregiving for children with developmental disabilities is associated with a poor antibody response to influenza vaccination[J]. Psychosom Med,2009,71(3):341-344.
[37] Madison AA, Shrout MR, Renna ME, et al.Psychological and behavioral predictors of vaccine efficacy: Considerations for COVID-19[J]. Perspect Psychol Sci, 2021,16(2):191-203.
[38] Qiu F, Liang CL, Liu H, et al.Impacts of cigarette smoking on immune responsiveness: Up and down or upside down?[J]. Oncotarget, 2017, 8(1): 268-284.
[39] Nomura Y, Sawahata M, Nakamura Y, et al.Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine[J].Vaccines (Basel),2021,9(9):1042.
[40] Barr T, Helms C, Grant K, et al.Opposing effects of alcohol on the immune system[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2016, 65:242-251.
[41] Nalpas B, Thepot V, Driss F, et al.Secondary immune response to hepatitis B virus vaccine in alcoholics[J]. Alcohol Clin Exp Res, 1993, 17(2): 295-298.
[42] Romeo J, Wärnberg J, Díaz LE, et al.Effects of moderate beer consumption on first-line immunity of healthy adults[J]. J Physiol Biochem, 2007, 63(2): 153-159.
[43] Messaoudi I, Asquith M, Engelmann F, et al.Moderate alcohol consumption enhances vaccine-induced responses in rhesus macaques[J].Vaccine,2013,32(1):54-61.
[44] Edwards KM, Booy R.Effects of exercise on vaccine-induced immune responses[J].Hum Vaccin Immunother,2013,9(4):907-910.
[45] de Araújo AL, Silva LC, Fernandes JR, et al. Elderly men with moderate and intense training lifestyle present sustained higher antibody responses to influenza vaccine[J]. Age (Dordr), 2015, 37(6): 105.
[46] Schuler PB, Lloyd LK, Leblanc PA, et al.The effect of physical activity and fitness on specific antibody production in college students[J]. J Sports Med Phys Fitness,1999,39(3): 233-239.
[47] Besedovsky L, Lange T, Born J.Sleep and immune function[J]. Pflugers Arch, 2012, 463(1): 121-137.
[48] Lange T, Dimitrov S, Bollinger T, et al.Sleep after vaccination boosts immunological memory[J]. J Immunol,2011,187(1):283-290.
[49] Benedict C, Brytting M, Markström A, et al.Acute sleep deprivation has no lasting effects on the human antibody titer response following a novel influenza A H1N1 virus vaccination[J]. BMC Immunol, 2012, 13:1.
[50] Bandaru P, Rajkumar H, Nappanveettil G.Altered or impaired immune response to hepatitis B vaccine in WNIN/GR-Ob rat: An obese rat model with impaired glucose tolerance[J]. ISRN Endocrinol, 2011, 2011:980105.
[51] Sheridan PA, Paich HA, Handy J, et al.Obesity is associated with impaired immune response to influenza vaccination in humans[J]. Int J Obes (Lond), 2012, 36(8):1072-1077.
[52] Eliakim A, Schwindt C, Zaldivar F, et al.Reduced tetanus antibody titers in overweight children[J]. Autoimmunity, 2006, 39(2):137-141.
[53] Chiu SK, Tsai KW, Wu CC, et al.Putative role of vitamin D for COVID-19 vaccination[J]. Int J Mol Sci, 2021, 22(16):8988.
[54] Lai YJ, Chang HS, Yang YP, et al.The role of micronutrient and immunomodulation effect in the vaccine era of COVID-19[J]. J Chin Med Assoc, 2021, 84(9): 821-826.
[55] Prietl B, Treiber G, Pieber TR, et al.Vitamin D and immune function[J]. Nutrients, 2013, 5(7): 2502-2521.
[56] Merzon E, Tworowski D, Gorohovski A, et al.Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: An Israeli population-based study[J]. FEBS J, 2020, 287(17): 3693-3702.
[57] Sundaram ME, Talbot HK, Zhu Y, et al.Vitamin D is not associated with serologic response to influenza vaccine in adults over 50 years old[J]. Vaccine, 2013, 31(16): 2057-2061.
[58] Principi N, Marchisio P, Terranova L, et al.Impact of vitamin D administration on immunogenicity of trivalent inactivated influenza vaccine in previously unvaccinated children[J]. Hum Vaccin Immunother, 2013, 9(5): 969-974.
[59] Antonen JA, Hannula PM, Pyhälä R, et al.Adequate seroresponse to influenza vaccination in dialysis patients[J]. Nephron, 2000, 86(1): 56-61.
[60] Semba RD, Munasir Z, Beeler J, et al.Reduced seroconversion to measles in infants given vitamin A with measles vaccination[J]. Lancet, 1995, 345(8961): 1330-1332.
[61] Bahl R, Kumar R, Bhandari N, et al.Vitamin A administered with measles vaccine to nine-month-old infants does not reduce vaccine immunogenicity[J].J Nutr,1999,129(8):1569-1573. |
粤公网安备 44011302000297号 